Sanofi Aktie

51,00 EUR ±0,00 EUR ±0,00 %

07.02.2025

STU

53,37 USD +0,50 USD +0,95 %

nachbörslich07.02.2025

BTT

Aktien, ETFs, Sparpläne & Kryptos zu Top-Konditionen beim Testsieger von finanztip.de handeln!

JETZT LOSLEGEN

Du hast schon ein ZERO-Konto? Direkt handeln bei ZERO!Bei einem anderen Broker handeln Smartphone

KGV19,43

WKN662283

ISINUS80105N1054

SymbolSNY

Sanofi Aktien News

Sortieren:Datum Meistgelesen

05.09.22GlobeNewswirePress Release: Late-breaking Dupixent® (dupilumab) data at ERS 2022 show consistent efficacy and safety profile for up to two years in children aged 6 to 11 years with moderate-to-severe asthma

05.09.22GlobeNewswirePress Release: Evolution of the Board of Directors

31.08.22GlobeNewswirePress Release: XenpozymeTM (olipudase alfa-rpcp) approved by FDA as first disease-specific treatment for ASMD (non-CNS manifestations)

30.08.22GlobeNewswirePress Release: FDA grants priority review to efanesoctocog alfa for people with hemophilia A

17.08.22GlobeNewswirePress Release: Sanofi provides update on amcenestrant clinical development program

12.08.22PR NewswirePublic health experts underscore importance of flu vaccinations to help reduce health inequities among high-risk populations

04.08.22GlobeNewswirePress Release: Sanofi and Innovent Biologics enter strategic collaboration to accelerate development of oncology medicines and expand presence in China

03.08.22PR NewswireSanofi appoints new Heads of U.S. General Medicines, and North America Vaccines and Consumer Healthcare

01.08.22PR NewswireSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sanofi - SNY

28.07.22GlobeNewswirePress Release: Strong execution in Q2 drives full-year 2022 guidance upgrade and delivers rich R&D news flow in Immunology and Rare Disease

26.07.22PR NewswireSanofi partners with Howard University in an unprecedented pharmacy fellowship program

22.07.22PR NewswireSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sanofi - SNY

14.07.22GlobeNewswirePress Release: Dupixent® (dupilumab) Phase 3 trial shows positive results in children 1 to 11 years of age with eosinophilic esophagitis

14.07.22PR NewswireSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sanofi - SNY

10.07.22GlobeNewswirePress Release: Pivotal data demonstrate once-weekly efanesoctocog alfa provides superior bleed protection compared to prior factor prophylaxis

10.07.22GlobeNewswirePress Release: Fitusiran prophylaxis reduced bleeds by 61% in people with hemophilia A or B, with or without inhibitors, compared to prior factor or bypassing agent prophylaxis

06.07.22PR NewswireSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sanofi - SNY

04.07.22GlobeNewswireSanofi Global Health launches nonprofit Impact® brand for 30 medicines in low-income countries

01.07.22PR NewswireSanofi flu vaccines licensed and approved for 2022-2023 influenza season, including CDC preferred higher-dose vaccines for adults 65+

28.06.22GlobeNewswirePress Release: Xenpozyme® (olipudase alfa) approved by European Commission as first and only treatment for ASMD

28.06.22GlobeNewswirePress Release: Nexviadyme® (avalglucosidase alfa) approved by European Commission as a potential new standard of care for the treatment of Pompe Disease

24.06.22GlobeNewswireAvailability of the Q2 2022 Memorandum for modelling purposes

24.06.22GlobeNewswirePress Release: Sanofi-GSK first to report a successful efficacy study against Omicron with COVID-19 Beta-containing vaccine

13.06.22GlobeNewswirePress Release: Sanofi-GSK next-generation COVID-19 booster delivers strong immune response against variants of concern, including Omicron

08.06.22GlobeNewswireSanofi launches its first Digital Accelerator fueled by new talent and focused on growth

07.06.22GlobeNewswirePress Release: FDA approves Dupixent® (dupilumab) as first biologic medicine for children aged 6 months to 5 years with moderate-to-severe atopic dermatitis

07.06.22PR NewswireFDA Approves Dupixent® (dupilumab) as First Biologic Medicine for Children Aged 6 Months to 5 Years with Moderate-to-severe Atopic Dermatitis

07.06.22GlobeNewswireSanofi launches 2022 global Employee Stock Purchase Plan for 86.000 people

02.06.22GlobeNewswirePress Release: Sanofi grants Regeneron worldwide exclusive license rights to Libtayo® (cemiplimab)

01.06.22PR NewswireSobi: FDA grants efanesoctocog alfa Breakthrough Therapy designation for haemophilia A

01.06.22GlobeNewswirePress Release: FDA grants efanesoctocog alfa Breakthrough Therapy designation for hemophilia A

31.05.22GlobeNewswirePress Release: FDA accepts Dupixent® (dupilumab) for priority review in adults with prurigo nodularis

31.05.22PR NewswireFDA Accepts Dupixent® (dupilumab) for Priority Review in Adults with Prurigo Nodularis

30.05.22GlobeNewswirePress Release: Update on Cialis® Rx-to-OTC Switch Actual Use Trial

20.05.22PR NewswireFDA Approves Dupixent® (dupilumab) as First Treatment for Adults and Children Aged 12 and Older with Eosinophilic Esophagitis

20.05.22GlobeNewswirePress Release: FDA approves Dupixent® (dupilumab) as first treatment for adults and children aged 12 and older with eosinophilic esophagitis

15.05.22GlobeNewswirePress Release: Sarclisa® (isatuximab) combination provides unprecedented median progression free survival in patients with relapsed multiple myeloma receiving a proteasome inhibitor therapy

11.05.22GlobeNewswirePress Release: New nirsevimab data analyses reinforce efficacy against RSV

04.05.22GlobeNewswirePress Release: Foundation S: Sanofi’s new philanthropic spearhead

03.05.22GlobeNewswirePress Release: Annual General Meeting of May 3, 2022

Sanofi News

Sanofi News: auf dieser Seite finden Sie alle Sanofi News und Nachrichten zur Sanofi Aktie. Dies beinhaltet die Agentur-Feeds auf finanzen.net, aber auch Sanofi News auf einer Vielzahl externer Seiten. Externe Links sind am entsprechenden Link-Symbol zu erkennen. Um Sanofi News auf externen Seiten zu lesen, folgen Sie einfach dem entsprechenden Link.